<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131690">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387594</url>
  </required_header>
  <id_info>
    <org_study_id>A7281008</org_study_id>
    <secondary_id>2011-001443-74</secondary_id>
    <nct_id>NCT01387594</nct_id>
  </id_info>
  <brief_title>Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs</brief_title>
  <acronym>TOSCA</acronym>
  <official_title>A Multi-center, Phase 1, Open-label Evaluation Of The Effect Of Pf-00547659 (Anti Madcam Monoclonal Antibody) On The Cerebrospinal Fluid (Csf) Lymphocytes In Volunteers With Crohn's Disease Or Ulcer Ulcerative Colitis Who Are Anti-tnf Inadequate Responders (Tosca)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is designed to show a lack of effect on white blood cells circulating in the spinal
      fluid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline (pre treatment) in absolute lymphocyte count in CSF in subjects with CD or UC after receiving 3 monthly doses of PF-00547659</measure>
    <time_frame>Week 9-11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of on treatment adverse events, withdrawal due to adverse events, and serious adverse events (SAEs) will be reported</measure>
    <time_frame>Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects developing anti-drug antibodies (ADA) to PF-00547659</measure>
    <time_frame>Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of injection site reactions and other hypersensitivity reactions</measure>
    <time_frame>Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ileitis</condition>
  <condition>Ileo-colonic and Colonic Crohn's Disease</condition>
  <condition>Granulomatous Colitis</condition>
  <condition>Regional Enteritis</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions prior to treatment. Control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions prior to and after 3 monthly injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lumbar puncture</intervention_name>
    <description>2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lumbar puncture</intervention_name>
    <description>1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females &gt;=18 and =&lt;75 years

          -  For CD subjects: hsCRP &gt; 5 mg/L and Harvey-Bradshaw Index &gt; 8 OR when HBI cannot be
             determined (ie if stoma is present) or hsCRP &lt; 5mg/L then: active lesions on
             colonoscopy or flexible sigmoidoscopy or active Crohn's disease on CT or MR
             enterography

          -  For UC subjects: diagnosis of UC &gt; 3 months; must have endoscopy to confirm active
             disease during screening; total mayo score of 6 to 12 points and moderate to severe
             disease on endoscopy

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  TB or active enteric infections

          -  Entero vesicular fistulae

          -  Prior use of natalizumab or vedolizumab

          -  Right or left heart failure including symptomatic diastolic dysfunction or
             unexplained elevation of troponin I (&gt;0.05 ng/mL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Wien Universitaetsklinik fuer Innere Medizin III Klinische Abteilung fuer Gastroenterologie und</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez, CHRU de Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis - CIC</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charit√©, Universitaetsmedizin Berlin, Campus Virchow Klinikum,</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center - University of Amsterdam, Dept. of Gastroenterology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7281008</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 21, 2016</lastchanged_date>
  <firstreceived_date>June 30, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease lumbar puncture anti-MAdCAM monoclonal antibody PF-00547659 Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Ileitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
